HCC | Clinical

ASCO GI 2021 OS Update: IMbrave150

February 22, 2021

Ruth He, MD, discusses the current treatment options for unresectable hepatocellular carcinoma.

Neoadjuvant Cabozantinib/Nivolumab Feasible For Borderline Resectable Patients with HCC

February 19, 2021

Preliminary data showing the neoadjuvant use of cabozantinib and nivolumab to be feasible for borderline resectable patients with hepatocellular carcinoma that can lead to potentially curative resection.

Challenges When Treating Patients With Hepatocellular Carcinoma

February 11, 2021

Al B. Benson, MD, discusses concerns in the hepatocellular carcinoma setting for treating patients for the best outcomes.

RDI and Ammonia Levels May Predict Tolerability of Lenvatinib in HCC

February 07, 2021

Good responses to lenvatinib were observed in patients with hepatocellular carcinoma who maintained a high relative dose intensity of 75% or greater.

Real-World Data for Lenvatinib Is Similar to Clinical Trials

February 01, 2021

Although lenvatinib has shown antitumor effects in hepatocellular carcinoma, long-term safety data are lacking.

FDA Grants Orphan Drug Designation to Uttroside-B in HCC

January 28, 2021

The FDA has granted an Orphan Drug Designation to the novel small molecule chemotherapeutic uttroside-B for the treatment of patients with hepatocellular carcinoma.

Pembrolizumab Monotherapy May Play Role in Treatment-Naive HCC

January 18, 2021

Pembrolizumab monotherapy demonstrated durable antitumor activity and encouraging effects on survival in an evaluation of patients with previously untreated hepatocellular carcinoma.

Second-Line Pembrolizumab Shows Continued OS and PFS Improvement in Advanced HCC

January 18, 2021

In patients with previously treated advanced hepatocellular carcinoma (HCC), single-agent pembrolizumab (Keytruda) maintained numerical improvement in survival (OS), updated findings randomized phase 3 KEYNOTE-240 trial show.

Survival Benefit Maintained With Atezolizumab Plus Bevacizumab in Advanced HCC

January 17, 2021

Results from the phase 3 IMbrave150 clinical trial showed that the combination of atezolizumab and bevacizumab continued to demonstrate improvement in survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.

Hepatocellular Carcinoma Treatment Landscape Evolving by the Minute, Abou-Alfa Says

January 17, 2021

Ghasson K. Abou-Alfa, MD, discusses the rapid evolution observed in the treatment landscape of hepatocellular carcinoma over the last few years.